

# Blood pressure and neuropathology: Late-life blood pressure association with cerebrovascular and Alzheimer's disease pathology

Zoe Arvanitakis, MD, MS, FANA, FAAN

Medical Director, Rush Memory Clinic  
Rush Alzheimer's Disease Center  
Professor, Department of Neurological Sciences  
Rush University Medical Center  
Chicago, IL

Immediate Past Chair, Geriatric Neurology Section, American Academy of Neurology

# Disclosures

- Presentation was created:
  - Solely by Dr. Arvanitakis who has no conflict of interest with regards to this presentation
  - Without any commercial support
- Funding for this work is through biomedical research grants by the **National Institutes of Health (NIH)**:
  - Dr. Arvanitakis is Principal Investigator on active grants:
    - R01 NS084965
    - RF1 AG059621
  - Additional funding for this work:
    - P30 AG010161
    - RF1 AG015819
    - R01 AG017917
    - RF1 AG022018
    - R01 AG011101
    - R01 AG051635
    - UH2 NS100599
    - R01 AG40039

# Rush Alzheimer's Disease Center (RADCC)

## Faculty (>30 and cross-departmental)

Neelum T. Aggarwal, MD  
Konstantinos Arfanakis, PhD  
Zoe Arvanitakis, MD, MS  
Lisa L. Barnes, PhD  
**David A. Bennett, MD**  
Patricia A. Boyle, PhD  
Katherine Blizinsky, PhD  
Aron Buchman, MD  
**Ana Capuano, PhD**  
Bob Dawe, PhD  
Jose Farfel, MD, PhD  
Debra Fleischman, PhD  
Chris Gaiteri, PhD  
Crystal Glover, PhD  
Duke Han, PhD  
Jeff Hausdorff, PhD  
Bryan James, PhD  
Alifiya Kapasi, PhD  
Namhee Kim, PhD  
Melissa Lamar, PhD  
Sue Leurgans, PhD  
Sukriti Nag, MD, PhD  
**Julie A. Schneider, MD, MS**  
Raj C. Shah, MD  
Sandra Swantek, MD  
Shinya Tasaki, PhD  
Yanling Wang, MD, PhD  
Robert Wilson, PhD  
Jingyun Yang, PhD  
Lei Yu, PhD

## Staff (>130)

Range of expertise, including data managers, statisticians, study managers, coordinators, research assistants, clinical experts, pathology and laboratory experts, educators, grant specialists, and administrative staff

## Funding

**National Institutes of Health**  
Illinois Department Public Health  
Philanthropy  
Industry  
Other

## Research Participants

**Religious Orders Study**  
**Rush Memory and Aging Project**  
**Minority Aging Research Study**  
African American Core  
Latino Core  
SANDS

## Strategic partners

RUMC  
Regional  
National  
International

Common conditions of  
older persons:  
neurologic and other

Longitudinal, community-based,  
clinical-pathologic research studies,  
for more than two decades

# Outline

PART 1. Review the association of blood pressure (BP) with common pathologies of dementia, specifically:

- Cerebrovascular disease and
- Alzheimer's disease (AD) pathology

PART 2. Explore the relation of BP with cognitive decline

# Religious Orders Study

- Began in 1993
- Funded by the National Institute on Aging
- > 1,450 older nuns, priests, and brothers without known dementia from >40 groups across the US
- All agreed to annual cognitive and motor testing
  - Complete neurological evaluation performed annually
  - > 95% follow-up of survivors with up to 24 time points
  - > 375 persons have developed dementia
- All agreed to brain donation at the time of death
  - > 90% autopsy rate with > 760 brain autopsies




# Memory and Aging Project

- Began in 1997
- Funded by the National Institute on Aging
- > 2,140 residents from about 40 retirement communities and senior housing from across the Chicago area
- All agreed to annual cognitive and motor testing, and blood draw
  - Complete neurological evaluation performed annually
  - > 90% follow-up of survivors with up to 21 time points
- All agreed to donate brain, spinal cord, muscle, and nerve at the time of death
  - > 85% autopsy rate with > 815 brain autopsies



# Minority Aging Research Study

- Began in 2004
- Funded by the National Institute on Aging
- > 750 older community-dwelling African Americans without known dementia, living in private residences or senior housing across the Chicagoland area
- All agreed to annual cognitive testing
- More recently, invited to participate in brain donation at time of death



# RANGE OF DATA FOR BROAD SCOPE OF STUDY



**BP**

Risk Factors: Medical, Psychological, Experiential, and genome-wide genotyping

**Genotypes**  
Affy 6.0/Illumina Quad  
1000G imputation

**Genotypes**  
Whole Genome Sequencing

DNA methylation, histone acetylation

**5mC Methylation**  
**5hmC Methylation**  
**H3K9Ac; H3K27Ac, ATACseq**

Next generation RNAseq, miRNA

**RNA profile**  
miRNA & RNAseq brain and monocytes

MS Proteomic and metabolomic

Proteomics, lipidomics, Metabolomics, brain and blood

Quantitative neurobiology

**Neuropathology**  
AD, CVD, LBD, HS, TDP, microgila

**Resilience Markers**  
Pre-synaptic proteins, LC neurons

**CVD, AD**

Structural & functional MRI

**FLAIR, MP Rage, DTI, SWI, rsfMRI**

**post-mortem MRI**  
DTI, Rage, T2

Quantitative clinical phenotype

**Cognitive Function**  
**19 tests annually**

**Motor Function**  
Disability, BMI, actigraphy, dynaport, sleep, behavioral economics, olfaction

**Cog decline**

Syndromic phenotype

**Clinical Diagnoses**  
AD, Stroke, PD,

**RANGE OF DATA FOR BROAD SCOPE OF STUDY**

# PART 1:

## BP and neuropathology

# OBJECTIVE

To examine associations of average and change in late-life blood pressure (BP) with cerebrovascular and Alzheimer's disease (AD) neuropathology in a large group of decedents followed longitudinally in vivo

Neurology 2018

# Blood pressure (BP)

- Measured at baseline and annually using an automated sphygmomanometer in an environment familiar to the research participant
- 3 values recorded and averaged
- For analyses, longitudinal data on each individual was aligned at death and we computed the standardized person-specific mean BP over time across the years (level) and slope of change in BP (change over time)
- Mean follow-up of 8 years (SD = 4.8)

**Table 1** Demographic, clinical, and neuropathologic characteristics of participants<sup>a</sup>

	Total (n = 1,288)
<b>Demographic</b>	
Age at death, y, mean (SD)	88.6 (6.7)
Female, n (%)	842 (65)
<i>APOE</i> ε4, n (%)	339 (26)
Education, y, mean (SD)	16.3 (3.7)
<b>Clinical</b>	
<b>BP, mm Hg, mean (SD)</b>	
SBP at baseline	136 (18)
SBP mean across study	134 (13)
DBP at baseline	72 (10)
DBP mean across study	71 (8)
History of hypertension at any time, n (%)	843 (66)
Antihypertensive medication use at any time, n (%)	1,122 (87)
Vascular risk factors at baseline, n (%) <sup>b</sup>	853 (66)
Vascular diseases at baseline, n (%) <sup>b</sup>	347 (28)

ROS, MAP,  
MARS subjects

**Neuropathologic**

<b>Brain infarcts, presence</b>	
<b>Any type of infarct (size or location), n (%)</b>	
Single infarct	260 (20)
Multiple infarcts	362 (28)
<b>Gross infarct(s), n (%)</b>	
Single infarct	222 (17)
Multiple infarcts	220 (17)
<b>Microinfarct(s), n (%)</b>	
Single infarct	226 (18)
Multiple infarcts	147 (11)
<b>Cortical infarct(s), n (%)</b>	
Single infarct	215 (17)
Multiple infarcts	124 (10)
<b>Subcortical infarct(s) present, n (%)</b>	
Single infarct	229 (18)
Multiple infarcts	222 (17)
<b>Vessel pathology,<sup>c</sup> n (%)</b>	
Atherosclerosis	452 (35)
Arteriolosclerosis	427 (33)
<b>AD pathology,<sup>d</sup> mean (SD)</b>	
Global score	0.7 (0.6)

# Analyses

- All analyses adjusted for age at death, sex, education and years in study
- Ordinal logistic regression analyses to determine the odds of separate cerebrovascular outcomes (one and more than one infarcts, increased severity of vessel pathology)
- Linear regression analyses to determine odds of AD pathology (overall and individual measures of plaques and tangles)

# BP and infarcts

**Table 2** Relationship of blood pressure with number of brain infarcts<sup>a</sup>

Outcome	SBP terms		DBP terms	
	Person-specific mean <sup>b</sup>	Person-specific slope <sup>b</sup>	Person-specific mean <sup>b</sup>	Person-specific slope <sup>b</sup>
Any infarct <sup>c</sup>	1.46 (1.24–1.72)	1.20 (1.03–1.39)	1.28 (1.09–1.50)	1.19 (0.92–1.55)
Gross infarct(s)	1.46 (1.22–1.74)	1.18 (1.01–1.38)	1.22 (1.02–1.45)	1.06 (0.80–1.41)
Microinfarct(s)	1.36 (1.13–1.64)	1.29 (1.09–1.52)	1.25 (1.04–1.50)	1.37 (1.03–1.84)
Cortical infarct(s)	1.20 (1.00–1.46)	1.23 (1.04–1.46)	1.09 (0.90–1.32)	1.34 (0.99–1.80)
Subcortical infarct(s)	1.46 (1.22–1.74)	1.14 (0.97–1.34)	1.22 (1.03–1.45)	1.07 (0.81–1.42)

Abbreviations: DBP = diastolic blood pressure; SBP = systolic blood pressure.

Data represent odds ratio (95% confidence interval).

<sup>a</sup> Ten ordinal logistic regression models, one for each of the 5 infarct outcomes (each categorized into 3 levels, as multiple, single, none [reference]) separately for the 2 predictors of SBP and DBP; all models adjusted for age at death, sex, education, and years in study; all infarcts are chronic.

<sup>b</sup> Terms for the standardized person-specific mean and declining slope of blood pressure are both included in a single analytic model.


<sup>c</sup> Any infarct refers to infarcts of any size (gross or microscopic) and location (cortical or subcortical).

Higher average late-life blood pressure (separately SBP and DBP), and independently a faster decline in SBP before death, are associated with increasing number of brain infarcts, both gross and microinfarcts

A person with a 1 SD SBP above the mean (147 vs 134 mmHg) would have a 46% increased odds of having one or more infarcts




**Figure 1** Relation of mean and slope of blood pressure with brain infarcts



Horizontal dashed line represents an odds ratio of 1. (A) Associations between the mean and declining slope of systolic blood pressure with each of the infarct outcomes (categorized as one, and more than one, compared to the reference of none), including any infarcts, gross infarcts and microinfarcts, and cortical and subcortical infarcts. (B) Associations for diastolic blood pressure with the same infarct outcomes.

# Effect modification by age

**Figure 2** Relation of mean and slope of blood pressure with brain infarcts, according to age



The effect of the mean SBP over time on infarcts was decreased with an increasing age at death (interaction of age with mean SBP)

# BP and AD

**Table 3** Relationship of blood pressure with Alzheimer disease neuropathology<sup>a</sup>

Outcome	SBP		DBP	
	Person-specific mean <sup>b</sup>	Person-specific slope <sup>b</sup>	Person-specific mean <sup>b</sup>	Person-specific slope <sup>b</sup>
<b>Global score</b>	0.031 (0.017), 0.065	0.005 (0.015), 0.727	-0.006 (0.017), 0.701	-0.006 (0.027), 0.826
<b>Neuritic plaques</b>	0.026 (0.022), 0.249	-0.004 (0.020), 0.832	-0.014 (0.022), 0.523	-0.033 (0.036), 0.366
<b>Diffuse plaques</b>	0.039 (0.021), 0.063	0.004 (0.019), 0.837	-0.002 (0.021), 0.926	0.017 (0.034), 0.612
<b>Neurofibrillary tangles</b>	0.037 (0.018), 0.038	0.020 (0.016), 0.212	0.006 (0.018), 0.731	-0.010 (0.003), 0.078

Abbreviations: DBP = diastolic blood pressure; SBP = systolic blood pressure.

Data represent estimate (SE), *p* value.

<sup>a</sup> Eight linear regression models, one for each of the 4 Alzheimer disease pathology outcomes (each transformed using the square root), and separately for SBP and DBP; all models adjusted for age at death, sex, education, and years in study.

<sup>b</sup> Terms for the standardized person-specific mean and declining slope of blood pressure are both included in a single analytic model.

Separately, some evidence for relation of higher SBP with more AD pathology, and with tangles in particular

# Weaknesses

- Observational study with cross-sectional design does not establish causation between risk factor and neuropathology
- Extent of neuropathology likely under-reported, as select regions examined
- Pathophysiologic mechanisms need further elucidation, e.g., mediation effects, taking into account range of co-existing clinical and pathologic factors
- White matter pathology not examined

# PART 2:

## BP and cognitive decline

# Level of BP (over the years) and change in cognitive function

	Estimate (SE), p value	
Cognitive decline	Mean SBP	Mean DBP
Global score	0.001 (0.003), 0.774	<b>0.010 (0.003), &lt;0.001</b>
Episodic memory	-0.002 (0.003), 0.600	<b>0.012 (0.003), &lt;0.001</b>
Semantic memory	0.003 (0.004), 0.443	<b>0.011 (0.004), 0.006</b>
Working memory	-0.001 (0.002), 0.811	<b>0.008 (0.003), 0.003</b>
Perceptual speed	0.001 (0.003), 0.661	<b>0.011 (0.003), &lt;0.001</b>
Visuospatial abilities	-0.001 (0.002), 0.807	<b>0.007 (0.002), 0.004</b>

Results suggest that a lower mean DBP is related to a faster decline in global cognitive function and in each of the cognitive domains

12 mixed effects models controlling for age, sex, education

3631 participants of ROS, MAP, or MARS who were followed annually (mean 9 years)

# SBP: relation of level with change (slope)

SBP level (average across study years), in quartiles	N	<b>SBP slope (mean)</b>	Lower 95% CL for Mean	Upper 95% CL for Mean
1	907	<b>-0.23</b>	-0.27	-0.20
2	908	<b>-0.39</b>	-0.43	-0.35
3	908	<b>-0.51</b>	-0.55	-0.46
4	908	<b>-0.76</b>	-0.81	-0.71

# DBP: relation of level with change (slope)

DBP level (average across study years), in quartiles	N	DBP slope (mean)	Lower 95% CL for Mean	Upper 95% CL for Mean
1	907	<b>0.07</b>	0.05	0.09
2	908	<b>-0.08</b>	-0.10	-0.06
3	909	<b>-0.15</b>	-0.17	-0.13
4	907	<b>-0.35</b>	-0.37	-0.32



# Preliminary interpretation

- These results suggest that there may be several pathways through which BP affects the brain:
  - SBP is associated with neuropathology (especially infarcts)
  - DBP is associated with cognitive decline
- More work needed to understand relation of SBP with DBP, and how levels and change in each are inter-related, and how they relate to change in cognition, and whether neuropathology mediates the relation of BP with cognition

Many remaining questions